A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel
K.N. Chi(University of Copenhagen), Howard I. Scher(Memorial Sloan Kettering Cancer Center), Charles J. Ryan(University of Minnesota), J. Li, Philip W. Kantoff(Convergent Science (United States)), Nicholas J. Vogelzang(Comprehensive Cancer Centers of Nevada), Thian Kheoh(Janssen (United States)), Johann S. de Bono(Royal Marsden NHS Foundation Trust), Joaquim Bellmunt(Dana-Farber Cancer Institute), Arun Azad(Peter MacCallum Cancer Centre), Anthony M. Joshua(St Vincent's Hospital Sydney), Bernhard J. Eigl(BC Cancer Agency), A. Molina(Janssen (Belgium)), Dana E. Rathkopf(Memorial Sloan Kettering Cancer Center), D.Y.C. Heng(University of Calgary), Karim Fizazi(Université de Lille)
Cited by 170
Related Papers
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
|New England Journal of Medicine|2010|5.5k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k